Polydeoxyribonucleotide, as a Novel Approach for the Management of Medication-Related Osteonecrosis of the Jaw: A Preliminary Observational Study
10.5856/JKDS.2018.11.2.57
- Author:
Junho JUNG
1
;
Hae Soo LIM
;
Deok Won LEE
Author Information
1. Department of Oral and Maxillofacial Surgery, School of Dentistry, Kyung Hee University, Seoul, Korea. verycutebear@hanmail.net
- Publication Type:Original Article
- Keywords:
Medication-related osteonecrosis of the jaw;
Polydeoxyribonucleotide
- MeSH:
Debridement;
Female;
Follow-Up Studies;
Humans;
Jaw;
Male;
Observational Study;
Osteonecrosis;
Polymers;
Receptor, Adenosine A2A;
Recurrence;
Wounds and Injuries
- From:Journal of Korean Dental Science
2018;11(2):57-61
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Polydeoxyribonucleotide (PDRN), consisting of a mixture of deoxyribonucleotide polymers, has been suggested to have anti-inflammatory effects and enhance angiogenesis as an adenosine A(2A) receptor agonist. The aim of this study was to report the effectiveness of PDRN as an adjuvant therapy after surgical debridement in MRONJ (medication-related osteonecrosis of the jaw) patients. MATERIALS AND METHODS: Five patients (1 male, 4 females, age 65~79 years) who were diagnosed with MRONJ stage 2 or 3 underwent surgical debridement and PDRN mucosal injection. After surgical debridement, patients were subject to daily injection with 1 ml of PDRN around the surgical wound for 14 days. RESULT: The patients' symptoms gradually disappeared. The surgical wound uneventfully healed, and no recurrence was observed during the follow-up period. CONCLUSION: Although further studies are required, the present study first describes the possibility of PDRN as a useful option for MRONJ treatment.
